AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
carglumic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3068 | 1188-38-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
carglumic acid could be helpful in lowering plasma ammonia levels over 400 micromol/L more rapidly
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 21 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 61 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,STK33,TEK,TGFBR1,ZAP70 | 13 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 18, 2010 | FDA | ORPHAN EUROPE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Off label use | 81.02 | 78.20 | 43 | 148 | 638292 | 41982852 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ammonia increased | 110.99 | 63.32 | 19 | 263 | 8231 | 110580786 |
| Off label use | 97.61 | 63.32 | 54 | 228 | 1500131 | 109088886 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AA05 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Amino acids and derivatives |
| FDA MoA | N0000184143 | Carbamoyl Phosphate Synthetase 1 Activators |
| FDA EPC | N0000184144 | Carbamoyl Phosphate Synthetase 1 Activator |
| CHEBI has role | CHEBI:71031 | orphan drug |
| CHEBI has role | CHEBI:71033 | carbamylphosphate synthetase I activator |
Related Drugs by ATC class:
A16AA Amino acids and derivatives 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperammonemia associated with N-acetylglutamate synthase deficiency | indication | ||
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.57 | acidic |
| pKa2 | 5.14 | acidic |
| pKa3 | 12.49 | acidic |
| pKa4 | 13.51 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 200MG | CARBAGLU | RECORDATI RARE | N022562 | March 18, 2010 | RX | TABLET, FOR SUSPENSION | ORAL | Jan. 22, 2028 | IN PEDIATRIC AND ADULT PATIENTS AS ADJUNCTIVE THERAPY TO STANDARD OF CARE FOR THE TREATMENT OF ACUTE HYPERAMMONEMIA DUE TO PROPIONIC ACIDEMIA (PA) OR METHYLMALONIC ACIDEMIA (MMA) |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbamoyl-phosphate synthase [ammonia], mitochondrial | Enzyme | POSITIVE ALLOSTERIC MODULATOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4030904 | VUID |
| N0000182969 | NUI |
| D07130 | KEGG_DRUG |
| 4030904 | VANDF |
| C1318649 | UMLSCUI |
| CHEBI:71028 | CHEBI |
| CHEMBL1201780 | ChEMBL_ID |
| DB06775 | DRUGBANK_ID |
| 121396 | PUBCHEM_CID |
| C528449 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7458 | IUPHAR_LIGAND_ID |
| 8008 | INN_ID |
| 5L0HB4V1EW | UNII |
| 401713 | RXNORM |
| 20611 | MMSL |
| 302324 | MMSL |
| 72491 | MMSL |
| d05656 | MMSL |
| 004390 | NDDF |
| 408045002 | SNOMEDCT_US |
| 412295009 | SNOMEDCT_US |
| 5L0HB4V1EW | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Carglumic acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-459 | TABLET, FOR SUSPENSION | 200 mg | ORAL | ANDA | 21 sections |
| Carbaglu | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52276-312 | TABLET, FOR SUSPENSION | 200 mg | ORAL | NDA | 25 sections |
| Carglumic acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-006 | TABLET, FOR SUSPENSION | 200 mg | ORAL | ANDA | 21 sections |
| Carglumic Acid | Human Prescription Drug Label | 1 | 71863-114 | TABLET, FOR SUSPENSION | 200 mg | ORAL | ANDA | 24 sections |